An Evaluation of Cabozantinib for the Treatment of Renal Cell Carcinoma: Focus on Patient Selection and Perspectives
Romain Iaxx,1 Felix Lefort,1,2 Charlotte Domblides,1– 3 Alain Ravaud,1,2 Jean-Christophe Bernhard,2,4 Marine Gross-Goupil1 1Department of Medical Oncology, Hôpital Saint-André, Bordeaux University Hospital, Bordeaux, France; 2Bordeaux University, Bordeaux, France; 3ImmunoConcEpt, CNRS UMR 5164, Bord...
Main Authors: | Iaxx R, Lefort F, Domblides C, Ravaud A, Bernhard JC, Gross-Goupil M |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2022-06-01
|
Series: | Therapeutics and Clinical Risk Management |
Subjects: | |
Online Access: | https://www.dovepress.com/an-evaluation-of-cabozantinib-for-the-treatment-of-renal-cell-carcinom-peer-reviewed-fulltext-article-TCRM |
Similar Items
-
Antitumor Effect of Cabozantinib in Bone Metastatic Models of Renal Cell Carcinoma
by: Michele Iuliani, et al.
Published: (2021-08-01) -
Safety and toxicity of cabozantinib monotherapy in patients with advanced renal cell carcinoma: a Russian multicenter observational study
by: Maria I. Volkova, et al.
Published: (2023-08-01) -
Mini-Review: Cabozantinib in the Treatment of Advanced Renal Cell Carcinoma and Hepatocellular Carcinoma
by: Rathi N, et al.
Published: (2020-05-01) -
Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors
by: Matteo Santoni, et al.
Published: (2019-12-01) -
Patients with metastatic renal cell carcinoma treated with cabozantinib in the Czech Republic: analysis of four cancer centers
by: Igor Richter, et al.
Published: (2022-03-01)